liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Henriksson, Martin
Alternative names
Publications (10 of 46) Show all publications
Henriksson, M., Jindal, R., Sternhufvud, C., Bergenheim, K., Sorstadius, E. & Willis, M. (2016). A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus. PharmacoEconomics (Auckland), 34(6), 569-585
Open this publication in new window or tab >>A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus
Show others...
2016 (English)In: PharmacoEconomics (Auckland), ISSN 1170-7690, E-ISSN 1179-2027, Vol. 34, no 6, p. 569-585Article, review/survey (Refereed) Published
Abstract [en]

Critiques of cost-effectiveness modelling in type 1 diabetes mellitus (T1DM) are scarce and are often undertaken in combination with type 2 diabetes mellitus (T2DM) models. However, T1DM is a separate disease, and it is therefore important to appraise modelling methods in T1DM. This review identified published economic models in T1DM and provided an overview of the characteristics and capabilities of available models, thus enabling a discussion of best-practice modelling approaches in T1DM. A systematic review of Embase(A (R)), MEDLINEA (R), MEDLINEA (R) In-Process, and NHS EED was conducted to identify available models in T1DM. Key conferences and health technology assessment (HTA) websites were also reviewed. The characteristics of each model (e.g. model structure, simulation method, handling of uncertainty, incorporation of treatment effect, data for risk equations, and validation procedures, based on information in the primary publication) were extracted, with a focus on model capabilities. We identified 13 unique models. Overall, the included studies varied greatly in scope as well as in the quality and quantity of information reported, but six of the models (Archimedes, CDM [Core Diabetes Model], CRC DES [Cardiff Research Consortium Discrete Event Simulation], DCCT [Diabetes Control and Complications Trial], Sheffield, and EAGLE [Economic Assessment of Glycaemic control and Long-term Effects of diabetes]) were the most rigorous and thoroughly reported. Most models were Markov based, and cohort and microsimulation methods were equally common. All of the more comprehensive models employed microsimulation methods. Model structure varied widely, with the more holistic models providing a comprehensive approach to microvascular and macrovascular events, as well as including adverse events. The majority of studies reported a lifetime horizon, used a payer perspective, and had the capability for sensitivity analysis. Several models have been developed that provide useful insight into T1DM modelling. Based on a review of the models identified in this study, we identified a set of best in class methods for the different technical aspects of T1DM modelling.

Place, publisher, year, edition, pages
ADIS INT LTD, 2016
National Category
Pharmaceutical Sciences
Identifiers
urn:nbn:se:liu:diva-129148 (URN)10.1007/s40273-015-0374-8 (DOI)000376104800004 ()26792792 (PubMedID)
Note

Funding Agencies|AstraZeneca

Available from: 2016-06-13 Created: 2016-06-13 Last updated: 2018-01-10
Geale, K., Henriksson, M. & Schmitt-Egenolf, M. (2016). Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics. British Journal of Dermatology, 174(3), 579-587
Open this publication in new window or tab >>Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics
2016 (English)In: British Journal of Dermatology, ISSN 0007-0963, E-ISSN 1365-2133, Vol. 174, no 3, p. 579-587Article in journal (Refereed) Published
Abstract [en]

Background Inequality in healthcare has been identified in many contexts. To the best of our knowledge, this is the first study investigating age inequality in the form of prescription patterns of biologics in psoriasis care. Objectives To determine whether patients with psoriasis have equal opportunities to receive biological medications as they age. If patients did not receive equal treatment, a subsequent objective was to determine the magnitude of the disparity. Methods A cohort of biologic-naive patients with psoriasis was analysed using Cox proportional hazards models to measure the impact of each additional year of life on the likelihood of initiating biological treatment, after controlling for sex, body mass index, comorbidities, disease activity and educational level. A supporting analysis used a nonparametric graphical method to study the proportion of patients initiating biological treatment as age increased, after controlling for the same covariates. Results The Cox proportional hazards model resulted in hazard ratios of a 1-year increase in age of 0.96-0.97 depending on calendar-year stratification, which implies that an increase in age of 30 years corresponds to a reduced likelihood of initiating biological treatment by 61.3-67.6%. The estimated proportion of patients initiating biological medication always decreased as age increased, at a statistically significant level. Conclusions Patients with psoriasis have fewer opportunities to access biological medications as they age. This result was shown to be applicable at all stages in a patients life course and was not only restricted to the elderly, although it implies greater disparities as the age difference between patients increases. These results show that inequality in access to biological treatments due to age is prevalent in clinical practice today. Further research is needed to investigate the extent to which this result is influenced by patient preferences.

Place, publisher, year, edition, pages
WILEY-BLACKWELL, 2016
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-127277 (URN)10.1111/bjd.14331 (DOI)000372805100027 ()26616003 (PubMedID)
Note

Funding Agencies|Swedish Board of Health and Welfare; Swedish Association of Local Authorities and Regions; Vasterbotten County Council

Available from: 2016-04-20 Created: 2016-04-19 Last updated: 2017-11-30
Janzon, M., Henriksson, M., Hasvold, P., Hjelm, H., Thuresson, M. & Jernberg, T. (2016). Long-term resource use patterns and healthcare costs after myocardial infarction in a clinical practice setting - results from a contemporary nationwide registry study. European Heart Journal - Quality of Care and Clinical Outcomes, 2, 291-298
Open this publication in new window or tab >>Long-term resource use patterns and healthcare costs after myocardial infarction in a clinical practice setting - results from a contemporary nationwide registry study
Show others...
2016 (English)In: European Heart Journal - Quality of Care and Clinical Outcomes, ISSN 2058-5225, Vol. 2, p. 291-298Article in journal (Refereed) Published
Abstract [en]

Aims Long-term contemporary nationwide data on resource use and healthcare costs after myocardial infarction (MI) in a clinical practice setting are not widely studied, and the aim of this study was to investigate resource use patterns and healthcare costs in patients with MI in a nationwide clinical practice setting.

Methods and results This retrospective cohort study included all patients identified in the compulsory Swedish nationwide patient register with a diagnosis of MI between 1 July 2006 and 30 June 2011. Cardiovascular hospitalization and outpatient visits data from the patient register were combined with data from the cause of death register and the drug utilization register. For a subset of patients, data were also available from a primary care register. Healthcare resource use patterns and annual costs [reported in 2014 euros (€) converted from Swedish kronor (SEK) using the exchange rate €1 = SEK 9.33)] were estimated for the year prior to the occurrence of MI as well as for a maximum follow-up period of 6 years post-MI. The study included 97 252 patients with a diagnosis of MI with a total number of 285 351 observation years. The majority of healthcare consumption occurred within the first year of MI where patients were on average hospitalized 1.55 times, made 1.08 outpatient care visits, and 3.80 primary care visits. In the long term, for the majority of resource use categories, average consumption was higher in the years after MI compared with the year prior to MI. Healthcare costs at 6 years of follow-up were approximately €20 000 of which €12 460 occurred in the first year, and the major part was attributed to hospitalizations.

Conclusion For patients with 6 years of follow-up after MI, healthcare costs were approximately €20 000. The major part of costs occurred in the first year after MI and was driven by hospitalizations

Place, publisher, year, edition, pages
European Society of Cardiology, 2016
National Category
Cardiac and Cardiovascular Systems Surgery
Identifiers
urn:nbn:se:liu:diva-130049 (URN)10.1093/ehjqcco/qcw019 (DOI)
Available from: 2016-07-06 Created: 2016-07-06 Last updated: 2017-03-01
Henriksson, M. (Ed.). (2016). Perspektiv på utvärdering, prioritering, implementering och hälsoekonomi: En hyllningsskrift till Per Carlsson. Linköping: Linköping University Electronic Press
Open this publication in new window or tab >>Perspektiv på utvärdering, prioritering, implementering och hälsoekonomi: En hyllningsskrift till Per Carlsson
2016 (Swedish)Collection (editor) (Other academic)
Abstract [sv]

Under alla år som jag arbetat med hälsoekonomi har Per Carlsson funnits närvarande. Mest intensivt som handledare under mina år som doktorand. När jag lärde känna Per år 2000 kom jag som nybakad nationalekonom till dåvarande CMT med en ganska snävt definierad nyttofunktion där fotboll var ett av de absolut dominerande attributen. Det har egentligen inte ändrats radikalt, men definitivt nyanserats en del under åren och det är delvis tack vare Per. Idol kan låta lite drastiskt, jag sprang inte omkring och bad om autografer eller att få fotas tillsammans med Per, men det är helt klart så att Per blev den första personen i min yrkeskarriär som jag med stor beundran såg upp till på ungefär samma sätt som man tidigare enbart gjort med sina idoler på fotbollsplanen. Med klokskap, sunt förnuft och en otrolig förmåga att hela tiden se de lite bredare sammanhangen blev han inte bara ett ovärderligt stöd i mitt eget arbete utan också en stor förebild mer generellt.

När det nu är dags för Per att trappa ner efter en lång och framgångsrik yrkeskarriär i akademins och hälso- och sjukvårdspolicyns tjänst kändes det både självklart och naturligt att försöka bidra med en bestående hyllning. Glädjande nog var vi många som delade den tanken och resultatet blev den antologi med samlade reflektioner som du nu håller i din hand. Bidragen spänner över ett brett fält från teorier om livskvalitet till praktiskt prioriteringsarbete och är talande för den bredd som genomsyrat Pers karriär. Vidare kan man säga att bidragen också kronologiskt inkluderar hela Pers era inom området då vi inleder med Bengt Jönsson som var handledare till Per och avslutar med Johanna Wiss som snart disputerar med Per som handledare.

Jag vill självklart också rikta ett stort tack till alla författare som bidragit till skriften. Den ger förhoppningsvis Per en möjlighet att reflektera över en livslång gärning inom akademi och hälso- och sjukvårdspolicy när det blir lite tid över i hängmattan framöver. Skriften ger också en bred populärvetenskaplig introduktion till aspekter som berör prioriteringar, utvärderingar, implementering och hälsoekonomi och det är min förhoppning att den kan uppskattas av alla som har intresse av dessa frågor.

Martin Henriksson

Maj 2016

Place, publisher, year, edition, pages
Linköping: Linköping University Electronic Press, 2016. p. 105
National Category
Health Care Service and Management, Health Policy and Services and Health Economy Social Sciences Interdisciplinary
Identifiers
urn:nbn:se:liu:diva-129521 (URN)9789176857441 (ISBN)
Note

Med bidrag från: Malin Andre, Eva Arvidsson, Lars Borgquist, Karin Bäckman, Niklas Ekerstad, Peter Garpenby, Martin Henriksson, Bengt Jönsson, Almina Kalkan, Barbro Krevers, Lars-Åke Levin, Lennart Nordenfelt, Kerstin Roback, Lars Sandman, Gustav Tinghög, Johanna Wiss

Available from: 2016-06-20 Created: 2016-06-20 Last updated: 2018-01-10Bibliographically approved
Jernberg, T., Hasvold, P., Henriksson, M., Hjelm, H., Thuresson, M. & Janzon, M. (2015). Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective.. European Heart Journal, 36(19), 1163-1170
Open this publication in new window or tab >>Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective.
Show others...
2015 (English)In: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 36, no 19, p. 1163-1170Article in journal (Refereed) Published
Abstract [en]

AIMS: Long-term disease progression following myocardial infarction (MI) is not well understood. We examined the risk of subsequent cardiovascular events in patients discharged after MI in Sweden.

METHODS AND RESULTS: This was a retrospective, cohort study linking morbidity, mortality, and medication data from Swedish national registries. Of 108 315 patients admitted to hospital with a primary MI between 1 July 2006 and 30 June 2011 (index MI), 97 254 (89.8%) were alive 1 week after discharge and included in this study. The primary composite endpoint of risk for non-fatal MI, non-fatal stroke, or cardiovascular death was estimated for the first 365 days post-index MI and Day 366 to study completion. Risk and risk factors were assessed by Kaplan-Meier analysis and Cox proportional hazards modelling, respectively. Composite endpoint risk was 18.3% during the first 365 days post-index MI. Age [60-69 vs. <60 years: HR (95% CI): 1.37 (1.30-1.45); 70-79 vs. <60 years: 2.13 (2.03-2.24); >80 vs. <60 years: 3.96 (3.78-4.15)], prior MI [1.44 (1.40-1.49)], stroke [1.49 (1.44-1.54)], diabetes [1.37 (1.34-1.40)], heart failure [1.57 (1.53-1.62)] and no index MI revascularisation [1.88 (1.83-1.93)] were each independently associated with a higher risk of ischaemic events or death. For patients without a combined endpoint event during the first 365 days, composite endpoint risk was 20.0% in the following 36 months.

CONCLUSIONS: Risk of cardiovascular events appeared high beyond the first year post-MI, indicating a need for prolonged surveillance, particularly in patients with additional risk factors.

National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:liu:diva-119668 (URN)10.1093/eurheartj/ehu505 (DOI)000356185300014 ()25586123 (PubMedID)
Available from: 2015-06-24 Created: 2015-06-24 Last updated: 2017-12-04
Janzon, M., James, S., Cannon, C. P., Storey, R. F., Mellström, C., Nicolau, J. C., . . . Henriksson, M. (2015). Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. Heart, 101(2), 119-25
Open this publication in new window or tab >>Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy
Show others...
2015 (English)In: Heart, ISSN 1355-6037, E-ISSN 1468-201X, Vol. 101, no 2, p. 119-25Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To investigate the cost effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes (ACS) in the Platelet Inhibition and Patient Outcomes (PLATO) study who were scheduled for non-invasive management.

METHODS: A previously developed cost effectiveness model was used to estimate long-term costs and outcomes for patients scheduled for non-invasive management. Healthcare costs, event rates and health-related quality of life under treatment with either ticagrelor or clopidogrel over 12 months were estimated from the PLATO study. Long-term costs and health outcomes were estimated based on data from PLATO and published literature sources. To investigate the importance of different healthcare cost structures and life expectancy for the results, the analysis was carried out from the perspectives of the Swedish, UK, German and Brazilian public healthcare systems.

RESULTS: Ticagrelor was associated with lifetime quality-adjusted life-year (QALY) gains of 0.17 in Sweden, 0.16 in the UK, 0.17 in Germany and 0.13 in Brazil compared with generic clopidogrel, with increased healthcare costs of €467, €551, €739 and €574, respectively. The cost per QALY gained with ticagrelor was €2747, €3395, €4419 and €4471 from a Swedish, UK, German and Brazilian public healthcare system perspective, respectively. Probabilistic sensitivity analyses indicated that the cost per QALY gained with ticagrelor was below conventional threshold values of cost effectiveness with a high probability.

CONCLUSIONS: Treatment of patients with ACS scheduled for 12 months' non-invasive management with ticagrelor is associated with a cost per QALY gained below conventional threshold values of cost effectiveness compared with generic clopidogrel.

TRIAL REGISTRATION NUMBER: NCT000391872.

National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-113396 (URN)10.1136/heartjnl-2014-305864 (DOI)000347459800008 ()25227704 (PubMedID)
Available from: 2015-01-17 Created: 2015-01-17 Last updated: 2017-12-05
Sabale, U., Bodegard, J., Sundstrom, J., Östgren, C. j., Nilsson, P., Johansson, G., . . . Henriksson, M. (2015). Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting. Primary Care Diabetes, 9(5), 330-337
Open this publication in new window or tab >>Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting
Show others...
2015 (English)In: Primary Care Diabetes, ISSN 1751-9918, E-ISSN 1878-0210, Vol. 9, no 5, p. 330-337Article in journal (Refereed) Published
Abstract [en]

Aims: To describe healthcare resource use patterns and estimate healthcare costs of newly diagnosed Type 2 diabetes mellitus (T2DM) patients in Sweden. Methods: Patients with a newly diagnosed T2DM between 1999 and 2009 were identified from 84 Swedish primary care centres. Healthcare resource use data, excluding pharmaceuticals, were extracted from electronic patient records and a national patient register, and reported as per patient mean number of primary care contacts, laboratory tests and hospitalizations. Per patient mean healthcare costs are reported as annual and cumulative costs. Results: During a median (maximum) of 4.6 (9.0) years follow-up; 38,956 patients (183,513 patient years) on average made 81 primary care contacts, was hospitalized 2.14 times, and took 31 laboratory tests. Mean per patient annual healthcare costs were (sic)4128 (95% CI, 4054-4199) the first year after diagnosis, (sic)2708 (95% CI, 2641-2776) the second year, and (sic)3030 (95% CI, 2854-3204) in year 9 (2012 values). Mean per patient cumulative healthcare costs were (sic)26,503 (95% CI, 26,025-26,970) at 9 years of follow-up. Hospitalizations accounted for the majority of healthcare costs. Conclusions: Although newly diagnosed T2DM patients require a substantial amount of healthcare services in primary care, hospitalizations account for the majority of healthcare costs. (C) 2015 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.

Place, publisher, year, edition, pages
ELSEVIER SCI LTD, 2015
Keywords
Type 2 diabetes mellitus; Healthcare utilization; Healthcare costs; Retrospective observational study
National Category
Health Care Service and Management, Health Policy and Services and Health Economy
Identifiers
urn:nbn:se:liu:diva-122105 (URN)10.1016/j.pcd.2015.01.001 (DOI)000361868100002 ()25631469 (PubMedID)
Note

Funding Agencies|AstraZeneca

Available from: 2015-10-19 Created: 2015-10-19 Last updated: 2017-12-01
Hager, J., Henriksson, M., Carlsson, P., Länne, T. & Lundgren, F. (2014). Changing Conditions - the same Conclusion: Cost-effective to Screen for Abdominal Aortic Aneurysm among 65-year-old Men, based on Data from an Implemented Screening Programme.
Open this publication in new window or tab >>Changing Conditions - the same Conclusion: Cost-effective to Screen for Abdominal Aortic Aneurysm among 65-year-old Men, based on Data from an Implemented Screening Programme
Show others...
2014 (English)Manuscript (preprint) (Other academic)
Abstract [en]

Background: Health economic analyses based on randomized trials have shown that screening for abdominal aortic aneurysm (AAA) cost-effectively decreases AAA-related as well as allcause mortality. However, results from running screening programmes now reveal substantially changed conditions in terms of prevalence, attendance rate, costs and mortality after intervention. Our aim was to evaluate whether screening for AAA among 65-year-old men on a general basis is cost-effective under current clinical practice.

Methods: A decision-analytic model, previously used to show the cost-effectiveness of an AAA-screening programme before decision to introduce screening in practice, was updated using results from implemented screening-programmes as well as data from contemporary published data and the Swedvasc registry.

Results: The base-case analysis showed that the cost per life-year gained and quality-adjusted life year (QALY) gained were 3252 € and 4231 €, respectively. The probability of screening being cost-effective was high.

Conclusion: Despite profound changes in disease pattern and AAA-management, the current results are similar to those reported almost 10 years ago, and thus screening 65-year-old men for AAA still appears to be cost-effective.

National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-102928 (URN)
Available from: 2014-01-08 Created: 2014-01-08 Last updated: 2017-03-27Bibliographically approved
Henriksson, M., Nikolic, E., Ohna, A., Wallentin, L. & Janzon, M. (2014). Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark. Scandinavian Cardiovascular Journal, 48(3), 138-147
Open this publication in new window or tab >>Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark
Show others...
2014 (English)In: Scandinavian Cardiovascular Journal, ISSN 1401-7431, E-ISSN 1651-2006, Vol. 48, no 3, p. 138-147Article in journal (Refereed) Published
Abstract [en]

Objectives. To evaluate the cost-effectiveness of treating patients with acute coronary syndromes (ACS) for 12 months with ticagrelor compared with generic clopidogrel in Sweden and Denmark. Design. Decision-analytic model to estimate lifetime costs, life-expectancy, and quality-adjusted life years (QALYs) with ticagrelor and clopidogrel. Event rates, healthcare resource use, and health-related quality of life during 12 months of therapy were estimated from the PLATelet inhibition and patient Outcomes (PLATO) trial. Beyond 12 months, quality-adjusted survival and costs were estimated conditional on events occurring during the 12 months of therapy. When available, country-specific data were employed in the analysis. Incremental cost-effectiveness ratios are presented from a healthcare perspective and a broader societal perspective including costs falling outside the healthcare sector in 2010 local currency. Results. The cost per QALY with ticagrelor compared with generic clopidogrel was SEK 25 022 and DKK 26 892 for Sweden and Denmark, respectively, from a healthcare perspective. The cost per QALY from a broader societal perspective was SEK 24 290 and DKK 25 051 for Sweden and Denmark, respectively. Conclusion. The cost per QALY of treating ACS-patients with ticagrelor compared with generic clopidogrel is below the conventional thresholds of cost-effectiveness in Sweden and Denmark.

Place, publisher, year, edition, pages
Informa Healthcare, 2014
Keywords
acute coronary syndrome; clopidogrel; cost-effectiveness analysis; quality-adjusted life years; ticagrelor
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-107246 (URN)10.3109/14017431.2014.902494 (DOI)000336974200002 ()24650118 (PubMedID)
Available from: 2014-06-10 Created: 2014-06-10 Last updated: 2017-12-05Bibliographically approved
Nikolic, E., Janzon, M., Hauch, O., Wallentin, L. & Henriksson, M. (2013). Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. European Heart Journal, 34(3), 220-228
Open this publication in new window or tab >>Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study
Show others...
2013 (English)In: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 34, no 3, p. 220-228Article in journal (Refereed) Published
Abstract [en]

The efficacy and safety of ticagrelor vs. clopidogrel in patients with acute coronary syndromes (ACS) are well documented in the PLATelet inhibition and patient Outcomes trial (PLATO). The aim of this study was to assess the long-term cost-effectiveness of treating ACS patients for 12 months with ticagrelor compared with generic clopidogrel.less thanbrgreater thanless thanbrgreater thanEvent rates, health-care costs, and health-related quality of life during 12 months of therapy with either ticagrelor or generic clopidogrel were estimated from PLATO. Beyond 12 months, quality-adjusted survival and costs were estimated conditional on whether a non-fatal myocardial infarction (MI), a non-fatal stroke, or no MI or stroke occurred during the 12 months of therapy. Lifetime costs, life expectancy, and quality-adjusted life years (QALYs) were estimated for both treatment strategies. Incremental cost-effectiveness ratios were presented from a health-care perspective in 2010 Euros (Euro) applying unit costs and life tables from a Swedish setting in the base-case analysis. Treatment with ticagrelor was associated with increased health-care costs of Euro362 and a QALY gain of 0.13 compared with generic clopidogrel, yielding a cost per QALY gained with ticagrelor of Euro2753. The cost per life year gained was Euro2372. The results were consistent in major subgroups. Sensitivity analyses showed a cost per QALY gained with ticagrelor of approximate to Euro7300 under certain scenarios.less thanbrgreater thanless thanbrgreater thanBased on clinical and health-economic evidence from the PLATO study, treating ACS patients with ticagrelor for 12 months is associated with a cost per QALY below generally accepted thresholds for cost-effectiveness.less thanbrgreater thanless thanbrgreater thanClinicalTrials.gov Identifier: NCT00391872.

Place, publisher, year, edition, pages
Oxford University Press (OUP): Policy B, 2013
Keywords
Acute coronary syndrome, Ticagrelor, Clopidogrel, Cost-effectiveness analysis, Quality-adjusted life years
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-89531 (URN)10.1093/eurheartj/ehs149 (DOI)000313831000013 ()
Note

Funding Agencies|AstraZeneca||Pfizer||Boehringer Ingelheim||Bristol-Myers Squibb||GlaxoSmithKline||Schering-Plough||Regado Biotechnologies||Athera Biotechnologies||Eli Lilly||

Available from: 2013-02-26 Created: 2013-02-26 Last updated: 2017-12-06
Organisations

Search in DiVA

Show all publications